Organogenesis (ORGO) Q4 2024 earnings summary

Executive summary

• Q4 2024 net revenue rose 27% year-over-year to $126.7 million, exceeding guidance due to strong customer demand and less market disruption from delayed LCD implementation; net income was $7.7 million versus a $0.6 million loss in Q4 2023.

• FY 2024 net revenue increased 11% to $482 million; net income was $0.9 million, down from $4.9 million in FY 2023.

• Advanced wound care led growth, up 27% in Q4 and 12% for the year; surgical and sports medicine up 24% in Q4 and 3% for the year.

• The finalized LCD, effective April 13, 2025, will significantly reduce the number of covered skin substitute products, positioning the company as a key beneficiary.

• Strategic focus remains on clinical data generation, product innovation, and advocacy for value-based payment reforms.

Financial highlights

• Q4 net revenue was $126.7 million, up 27% year-over-year, with advanced wound care revenue at $119 million (+27%) and surgical/sports medicine at $8 million (+24%).

• Q4 gross profit was $96 million (75.5% margin), up from 72.1% last year; FY 2024 gross profit was $366.3 million (76% margin), up from $326.7 million (75%) in FY 2023.

• Q4 operating income was $10.2 million, compared to a $1.3 million loss last year; GAAP net income was $7.7 million, up from a $0.6 million loss.

• Adjusted EBITDA for Q4 was $18.2 million (14.4% margin), up from $7.5 million (7.5% margin) last year; FY 2024 adjusted EBITDA was $49.8 million (10.3% margin).

• FY 2024 included $18.8 million in impairment and $4 million in write-down expenses.

Outlook and guidance

• FY 2025 net revenue guidance is $480–$535 million (flat to +11% year-over-year), with advanced wound care expected at $450–$500 million and surgical/sports medicine at $30–$35 million.

• GAAP net income guidance: $9.5–$38.8 million; Adjusted EBITDA: $43.6–$83.2 million.

• Gross margin expected at 76–78%; operating expenses flat to down 2% year-over-year (GAAP), with non-GAAP opex up 3–6% due to clinical and regulatory investments.

• Challenging environment expected in H1 2025 due to LCD transition, with significant improvement anticipated from Q3 onward.

• Key milestone: ReNu BLA submission expected by end of 2025.